🇺🇸

US SEC Filing Intelligence

· monthly

US Pre-Market SEC Filings Roundup — July 01, 2026

Overnight SEC filings from June 30 to July 1, 2026, reveal a market dominated by capital return programs, SPAC extension maneuvers, and a significant biotech acquisition. A clear theme of aggressive shareholder returns emerges, with Aegon launching a new EUR 200 million buyback and Sumitomo Mitsui executing a large JPY 76 billion repurchase, though lagging its authorization pace. The SPAC space shows continued stress, with Plum Acquisition Corp. IV seeking a shareholder vote to extend its business combination deadline, offering non-redemption incentives. The most material event is the completed acquisition of Aptose Biosciences by Hanmi Pharmaceuticals for C$2.41 per share, a definitive end for the biotech. On the negative side, InnSuites Hospitality Trust received a NYSE American delisting notice due to a stockholders' deficit, while Terra Innovatum Global reported a sharply widening net loss, though it holds a strong cash position. Insider activity was mixed, with a notable open-market purchase by a Hallador Energy director signaling confidence in the energy sector, countered by a large sale by a United Microelectronics Corp vice president. Overall, the filings point to a bifurcated market: established companies returning capital to shareholders, while earlier-stage and stressed entities focus on survival and restructuring.

24 high priority 26 medium 50 total filings
· daily

Biotech Small-Cap Approvals — June 30, 2026

This digest covers 7 FDA approvals from June 24-25, 2026, all classified as 'FALLBACK' types with zero NMEs, zero biosimilars, and zero label expansions. The dominant theme is generic/biosimilar competition in mature therapeutic areas, with no novel drug approvals or breakthrough signals. The highest-conviction signal is the label expansion for FOSAPREPITANT (NAVITRUX) by AVYXA HOLDINGS, which is the sole bullish event, though commercial details are undisclosed. Key risk: the absence of NMEs and the high volume of generic entries (6 of 7 approvals) signals a weak innovation pipeline for small-cap biotech this period, with potential pricing pressure on originator drugs like ICOSAPENT ETHYL (Vascepa) and FERRIC CARBOXYMALTOSE (Injectafer).

7 total filings
· daily

Big Pharma Approvals — June 30, 2026

During the single-day period of June 30, 2026, the FDA issued one label expansion approval for risankizumab-rzaa (SKYRIZI) by AbbVie Inc., classified as a 'fallback' type with a bullish signal. There were zero NMEs, zero biosimilars, and zero other label expansions, making this a low-volume but directionally positive event for AbbVie's immunology franchise. The dominant therapeutic area theme is immunology/dermatology, with SKYRIZI's expansion reinforcing AbbVie's strategy to extend its blockbuster IL-23 inhibitor into additional indications. The highest-conviction signal is the label expansion itself, which provides incremental commercial runway for SKYRIZI as AbbVie navigates HUMIRA biosimilar erosion. Key watch items include the specific indication approved (not disclosed in the data) and whether this expansion opens a new patient population or deepens an existing one.

1 total filings
· daily

Orphan Drug Approvals — June 30, 2026

This single-approval period from June 30, 2026, features a label expansion for AbbVie Inc.'s risankizumab-rzaa (Skyrizi), classified as a 'fallback' approval type with a moderately bullish signal. The approval mix shows zero NMEs, biosimilars, or other high-impact events, making this a low-velocity digest with no new therapeutic area clustering. The highest-conviction signal is the Skyrizi label expansion itself, which reinforces AbbVie's immunology franchise depth and provides incremental commercial optionality, though the absence of peak sales or exclusivity data limits conviction. The key risk is the lack of disclosed commercial details, which prevents full assessment of revenue impact or competitive positioning.

1 total filings
· daily

New Drug Approvals (Original) — June 30, 2026

This period covers 7 FDA approvals, all classified as 'Other' (primarily biosimilars and one label expansion), with zero NMEs or true biosimilars. The dominant theme is generic/biosimilar competition, with multiple entrants targeting established brands like FERRIC CARBOXYMALTOSE and ICOSAPENT ETHYL. The highest-conviction signal is the label expansion for FOSAPREPITANT (NAVITRUX) by AVYXA HOLDINGS, which is the only bullish event. Key risk is the lack of NME approvals, signaling a quiet period for innovative drug catalysts, while the biosimilar wave pressures originator pricing power.

7 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 30, 2026

The S&P 500 Technology sector filings this period reveal a sector in transition, with governance and executive compensation under intense shareholder scrutiny, while insider selling at a key semiconductor firm signals potential near-term headwinds. NVIDIA's annual meeting showed strong support for management and a shift toward simpler governance, but shareholders rejected ESG-related proposals, indicating a focus on core business. Snowflake's meeting was more contentious, with a clear 'say-on-pay' failure and a shareholder-driven push for majority voting in director elections, reflecting growing investor activism in tech. The most material development is the significant insider selling by Micron Technology's CEO, totaling over $7.5 million across two filings, all executed under a 10b5-1 plan, which may temper near-term bullish sentiment on memory stocks. Period-over-period comparisons were not available in these filings, but the insider activity and governance votes provide actionable signals. The sector shows a bifurcation between companies with strong management support (NVIDIA) and those facing shareholder pushback (Snowflake), while insider selling at Micron warrants close monitoring for further weakness.

4 high priority 4 total filings
· daily

Nasdaq 100 Stocks SEC Filings — June 30, 2026

The four filings from NASDAQ-100 constituents reveal a mixed picture: NVIDIA's annual meeting passed key governance reforms (simple majority voting) but rejected three ESG-focused shareholder proposals, signaling a potential shift in investor priorities toward operational control over social issues. Insider selling dominates the signals, with Micron Technology's CEO Sanjay Mehrotra executing a massive $7.6 million in stock sales across two filings (totaling 6,619 shares at ~$1,132-$1,182), while Alphabet director Frances Arnold sold a token $39,300 worth of stock. No period-over-period comparisons, forward-looking guidance, or capital allocation data were available in these filings, limiting trend analysis. The concentrated insider selling in Micron, combined with the absence of bullish insider activity, creates a bearish undercurrent for the semiconductor sector. NVIDIA's governance overhaul could be a positive catalyst for long-term shareholder alignment, but the lack of financial metrics or guidance changes leaves investors with limited actionable data beyond insider behavior.

3 high priority 1 medium 4 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — June 30, 2026

This digest of 19 major shareholder filings reveals a period of significant portfolio restructuring, with notable activist-driven M&A catalysts and insider position adjustments. Key themes include three completed or proposed take-private transactions (Janus Henderson at $52/share, ProAssurance at $25/share, and Nano Dimension at $1.60/share), suggesting a wave of conviction-based exits by major holders. Insider activity is mixed: while Toyota deepened its strategic commitment to Joby Aviation via a manufacturing JV, Andreessen Horowitz executed a substantial block sale of Nautilus Biotechnology at $2.00/share, reducing its stake by ~28%. Period-over-period data shows passive investors (13G filers) accumulating positions in Appian (6.8%) and TheRealReal (7.6%), while activist filers like Trian and Magnetar fully exited via mergers. The most critical development is Tang Capital's unsolicited $1.60/share bid for Nano Dimension, representing a 12-34% premium over recent insider purchase prices, creating an immediate catalyst. Portfolio-level patterns indicate a rotation from small-cap biotech and specialty finance into cash-generating precious metals and enterprise software, with Elliott maintaining a dominant 64.7% position in Triple Flag Precious Metals.

14 high priority 5 medium 19 total filings
· daily

S&P 500 Financials Sector SEC Filings — June 30, 2026

The four filings from the S&P 500 Financials sector reveal a mixed landscape of operational risk, insider sentiment, and strategic capital deployment. The most critical development is a cybersecurity incident at Aflac Japan, which exposed sensitive policyholder and bank data, posing reputational and regulatory risks despite being contained to Japan. This event underscores a sector-wide vulnerability to cyber threats, particularly for firms with complex international operations. Conversely, a significant insider sale by Visa's CEO, executed under a 10b5-1 plan, signals potential valuation concerns or personal portfolio diversification at a time of high share prices. BlackRock's filing for share issuance tied to the HPS Investment Partners acquisition indicates continued strategic consolidation in asset management, with deferred consideration linked to performance milestones. A minor operational delay at Morgan Stanley Capital I Trust highlights cash flow timing risks in commercial real estate trusts. No period-over-period comparisons were available in the enriched data, limiting trend analysis, but the filings collectively point to cybersecurity, insider activity, and M&A execution as key areas for investor focus.

1 high priority 3 medium 4 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — June 30, 2026

The latest batch of 21 SEC filings from the S&P 500 Consumer Staples sector reveals a sector dominated by routine, non-discretionary insider transactions, primarily tax withholdings on equity awards at General Mills and director stock awards at Campbell's. The most notable outlier is a significant, open-market sale by the Chief People Officer of J M Smucker Co, which introduces a bearish signal for that company. Across the filings, there is a distinct lack of forward-looking guidance, M&A activity, or financial performance data, limiting the ability to identify broad sector trends. The key actionable intelligence is concentrated on the insider activity at J M Smucker, which warrants further investigation, while the General Mills and Campbell's filings suggest a period of stability and routine corporate governance. The absence of any period-over-period comparisons or financial metrics from these filings prevents the identification of revenue or margin trends across the portfolio.

21 high priority 21 total filings
· daily

S&P 500 Industrials Sector SEC Filings — June 30, 2026

The single filing in this digest, from Paychex Inc., falls outside the core S&P 500 Industrials focus (Aerospace, Defense, Machinery, Transportation, Construction) as it operates in the Human Capital Management (HCM) and payroll services sector. Despite this, the insider transaction data provides a clear, actionable signal. Director Joseph M. Tucci executed a multi-step transaction involving the exercise of options, tax withholding, and a direct market sale, resulting in a net reduction of his holdings. The sale price of ~$98.25 per share, combined with the overall negative sentiment from the transaction pattern, suggests a potential lack of conviction at current valuation levels. While no period-over-period financial trends or forward-looking guidance are available from this single filing, the insider activity is the dominant data point, warranting a bearish watch on the stock. This filing is excluded from the sector themes and broader industrial analysis due to its sector mismatch.

1 high priority 1 total filings
· daily

S&P 500 Energy Sector SEC Filings — June 30, 2026

The three filings from the S&P 500 Energy sector reveal a mixed picture: insider selling at Valero Energy contrasts with routine director compensation at Halliburton, while Devon Energy's annual meeting shows strong shareholder support with minor dissent. No period-over-period comparisons, forward-looking guidance, or capital allocation data were available in these filings, limiting trend analysis. The most notable signal is the insider sale by Valero's SVP, which may indicate management caution despite the company's strong market position. Overall, the sector appears stable but lacks catalysts for near-term alpha generation from these filings alone.

3 high priority 3 total filings
· daily

US Material Events SEC 8-K Filings — June 30, 2026

This Material Events Monitor digest covers 50 filings from June 30, 2026, revealing a market dominated by significant capital structure events, strategic M&A, and management transitions. The most critical development is the $1.49B divestiture of SSR Mining's Çöpler mine, which dramatically transforms its financial profile, converting a net loss into substantial net income on a pro-forma basis. A wave of refinancing and capital raising is evident, with companies like MarineMax, Seadrill, and Main Street Capital securing improved credit terms, while others like Creative Realities and Eos Energy pursue dilutive equity or complex JV structures to fund operations. The M&A landscape is active, highlighted by the transformative $8.1B revenue merger between Patrick Industries and LCI Industries and a high-risk SPAC merger for pre-revenue nuclear startup NuCube Energy. Insider activity is sparse but notable, with several board appointments and CFO changes signaling strategic shifts. A key portfolio-level pattern is the tightening of financial covenants, as seen with HighPeak Energy, indicating lenders are demanding greater discipline. The overall sentiment is cautiously positive, driven by strategic repositioning and improved liquidity, but tempered by reliance on uncertain milestones, potential dilution, and the high-risk nature of several pre-revenue ventures.

50 high priority 50 total filings
· daily

Insider Trading Pulse — June 30, 2026

The June 30, 2026, insider trading digest reveals a market dominated by routine compensation-related transactions (awards, option exercises, tax withholdings) rather than conviction-driven buying or selling, signaling a neutral-to-cautious sentiment among corporate insiders. Notable exceptions include a clear bullish signal from TSMC's VP Tien Bor-Zen, who made two open-market purchases totaling ~$152K, and a bearish signal from NetEase's General Counsel, who sold $1.28M in shares. A cluster of insider selling emerged in the financial sector, with executives at Peapack Gladstone and Globe Life cashing out, while multiple directors at Principal Financial Group and Terex received routine stock awards. The most significant transaction by value was Opera Ltd's Executive Chairman Zhou Yahui disposing of ~$10.7M in shares, a large-scale move that warrants monitoring. Overall, the data suggests insiders are not aggressively signaling directional bets, with the majority of filings reflecting pre-planned compensation events rather than discretionary trades.

50 high priority 50 total filings
· daily

Global High-Priority Regulatory Events — June 30, 2026

The 50 filings for June 30, 2026, reveal a market dominated by M&A activity, with a significant number of deals facing delays, particularly those involving Indian companies and cross-border transactions. A clear theme of corporate restructuring is evident, with several companies pursuing mergers of wholly-owned subsidiaries to simplify structures and achieve synergies. The insolvency landscape is active, with a notable victory for Vikram Solar Limited, where an NCLAT order set aside an improper insolvency admission, and a high-risk situation at Aksh Optifibre where a promoter is appealing a CIRP order. Defaults are concentrated in the real estate and textile sectors, with Ansal Housing and Harish Textile Engineers both reporting principal payment defaults. The most material positive development is SSR Mining's $1.49 billion sale of its Çöpler mine, which dramatically improves its financial position and removes a major operational risk. Overall, the period is marked by cautious optimism in M&A, ongoing stress in specific sectors, and a focus on regulatory compliance and capital allocation.

50 high priority 50 total filings
· daily

Dow Jones 30 Stocks SEC Filings — June 30, 2026

The four filings from Dow 30 constituents reveal a bifurcated landscape: consumer discretionary giant NIKE is navigating a strategic transition with a one-time tariff benefit masking underlying top-line weakness, while financial services leader VISA sees its CEO execute a large, pre-planned stock sale. The two Verizon Master Trust filings are purely operational debt issuances and legal formalities, offering no new strategic or financial signals for the parent company. The key portfolio-level trend is the divergence between operational performance and financial engineering—NIKE's core revenue is flat to down, yet profitability is artificially inflated by a non-recurring $986M tariff recovery. Meanwhile, VISA's insider sale, though under a 10b5-1 plan, represents a significant monetization event by the CEO. The overall picture is one of caution for NIKE and VISA, with no positive catalysts emerging from the filings.

2 high priority 2 medium 4 total filings
· daily

US SEC Filings Daily Market Digest — June 30, 2026

Today's filings reveal a market bifurcated between aggressive capital deployment (M&A, IPOs, debt raises) and operational distress signals. The most significant theme is a wave of strategic pivots and divestitures: SSR Mining's $1.49B sale of its Çöpler mine marks a clean exit from a troubled asset, while ON Semiconductor's planned acquisition of Synaptics targets a $100B edge AI TAM. Conversely, Harbor Diversified's 93.6% revenue collapse and Sadot Group's $1,000 asset sale highlight deep operational distress. The IPO pipeline is active, with Matternet (drone logistics), Idaho Copper, and two SPACs filing, though all carry significant execution risk. Capital allocation is mixed: Realty Income is raising €600M in debt, while News Corp maintains a $1B buyback. Cybersecurity risk is elevated, with Aflac Japan's data breach exposing sensitive customer data. Insider activity is sparse but notable, with Rani Therapeutics' new CFO receiving a large equity inducement grant. Overall, the digest points to a market favoring companies with clear strategic narratives and punishing those with deteriorating fundamentals.

21 high priority 29 medium 50 total filings
· daily

S&P 500 Consumer Discretionary Sector SEC Filings — June 30, 2026

The two filings within the S&P 500 Consumer Discretionary stream reveal a stark divergence between headline profitability and underlying operational health. NIKE Inc. reported a superficially strong Q4 FY26 with a net income surge of 407%, driven entirely by a one-time $986M benefit from expected IEEPA tariff recoveries, which inflated gross margins by nearly 900 bps. However, this masks a deeply troubling trend of declining core demand, with NIKE Direct revenues falling 7% YoY and Converse revenues plunging 32%. Full-year revenue was flat, and adjusted EPS of $0.20 paints a picture of significant underlying weakness. Conversely, the filing for TARGET CORP offers a clear negative signal of insider conviction, with an Executive Officer selling a substantial portion of holdings. The key portfolio-level theme is that government intervention (tariff recovery) is artificially and unsustainably propping up profitability in the face of declining operational performance, creating a high-risk, low-quality earnings environment. Meanwhile, insider selling at a major retailer signals internal caution about the consumer spending outlook.

1 high priority 1 medium 2 total filings
· daily

S&P 500 Healthcare Sector SEC Filings — June 30, 2026

This batch of 13 filings from the S&P 500 Healthcare stream is dominated by routine insider transactions. The most notable signal is a net insider selling bias, headed by Vertex Pharmaceuticals' CMO and Edwards Lifesciences' TAVR lead, both executing pre-planned sales. In contrast, Thermo Fisher and Pfizer showed exclusively neutral signals, with multiple directors receiving phantom stock units—a non-cash compensation routine that indicates no active insider concern. Overall, the aggregate period-over-period data across these specific filings is sparse, preventing deep trend analysis. The key actionable insight is the divergence: one group of executives is monetizing equity, while boards at two mega-caps are transacting only via compensation. No guidance changes, capital allocation shifts, or material transaction details were filed, making this a low-signal batch with minor micro-level concerns for the two sellers.

13 high priority 13 total filings
· daily

US Earnings Financial Results SEC Filings — June 30, 2026

This digest of 14 financial results filings reveals a bifurcated market where a few companies (Jabil, Progress Software, Apogee Enterprises) demonstrate strong operational leverage and shareholder returns, while a larger cohort (Harbor Diversified, Beneficient, ProPhase Labs, Tel Instrument) faces severe revenue declines, cash burn, and balance sheet deterioration. Period-over-period comparisons highlight a trend of revenue contraction and widening losses across 7 of 14 filers, with notable outliers like Jabil (revenue +11.8% YoY, net income +23.9%) and Progress Software (license revenue +35.8% YoY). Capital allocation patterns diverge sharply: Jabil and Apogee are aggressively buying back shares, while ProPhase Labs and Guru App Factory face existential liquidity crises. Insider activity is sparse but negative where present, and forward-looking guidance is limited, creating a catalyst vacuum for most small-cap names. The most critical developments include Beneficient's massive loss swing due to a $62.8M arbitration accrual, Harbor Diversified's 93%+ revenue collapse, and ProPhase Labs' descent into negative equity.

14 high priority 14 total filings